Approval · Notice of Compliance 2596 · 2001

STREPTASE: Notice of Compliance 2596

Issued January 11, 2001

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 2596
Date: January 11, 2001
Company: Aventis Pharma Inc.Laval, Quebec, Canada
Product type: Biologic
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Manufacturer name change
Therapeutic class: Fibrinolytic agent

Products in this notice

Brand	DIN	Status today
STREPTASE	02018993	Cancelled Post Market
STREPTASE	02019000	Cancelled Post Market
STREPTASE	02019019	Cancelled Post Market

Medicinal ingredients

STREPTOKINASE 250,000 UNIT per VIAL
STREPTOKINASE 750,000 UNIT per VIAL
STREPTOKINASE 1,500,000 UNIT per VIAL